Skip to main content
SpringerLink
Log in

New targets in breast cancer

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

In the past few years, the therapeutic strategies for breast cancer have broadened substantially beyond endocrine therapy, chemotherapy, and human epidermal growth factor receptor 2-targeted agents to include several new drugs with unique mechanism of actions including antibody–drug conjugates, inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, cyclin-dependent kinases 4/6, histone deacetylases and the poly ADP ribose polymerase as well as immune checkpoint modulators. Novel clinical trial designs are also being implemented in the clinic to assess the therapeutic potential of targeting rare molecular abnormalities observed in breast cancers (fibroblast growth factor receptor amplification, inactivating mutations in BRCA, activating mutations in HER2, epidermal growth factor receptor, c-Kit, Akt, etc.).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203(2):661–71.

    Article  PubMed  Google Scholar 

  3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

    Article  Google Scholar 

  5. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.

    Article  CAS  PubMed  Google Scholar 

  7. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Ro J, et al. O1-030PHASE II STUDY OF PALBOCICLIB (PD-0332991) + LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER + /HER2- ADVANCED BREAST CANCER. Ann Oncol. 2013;24(Suppl 9):ix32–3.

    Article  Google Scholar 

  8. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–35.

    Article  CAS  PubMed  Google Scholar 

  9. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–67.

    Article  PubMed  Google Scholar 

  11. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Yardley DA, Noguchi S, Pritchard KI, Burris HA, III, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR( + ) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90.

    Article  CAS  PubMed  Google Scholar 

  15. Iwata H, et al. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. ASCO Meeting Abstracts. 2013;31:TPS650.

    Google Scholar 

  16. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29(23):3126–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. O’Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(Suppl; abstr 505).

  18. Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–45.

    Article  CAS  PubMed  Google Scholar 

  19. Goncalves A IN, Campone M, et al. PIKHER2: a phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer. J Clin Oncol. 2013;31(Suppl; abstr TPS663).

  20. Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant chemotherapy for high-risk breast cancer. First efficacy results from the I-SPY 2 trial. Program and abstracts of the 2013 San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio, Abstract S5-02; 2013.

  21. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90.

    Article  CAS  PubMed  Google Scholar 

  22. Mina LA, Wainberg ZA, Ramanathan RK, et al. Update on first-inhuman trial of novel PARP inhibitor BMN 673 in patients with solid tumors. Poster presented at 2013 San Antonio Breast Cancer Symposium, December 10–14, 2013, San Antonio, P2-09–02.

  23. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Traina TA. 10P A phase 1 open-label study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer. Ann Oncol. 2014;25(Suppl_1):i4. doi:10.1093/annonc/mdu064.

    Article  Google Scholar 

  25. Capper CP, Johnson MD, Larios JM, Rae JM. Abstract 5568: CYP17A1 and abiraterone: implications for breast cancer endocrine therapy. Cancer Res. 2014;74(Suppl. 19):5568.

    Article  Google Scholar 

  26. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US). 2014 Dec 15. Identifier NCT01381874, randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER + ) metastatic breast cancer (MBC). 2014. https://clinicaltrials.gov/ct2/show/NCT01381874.

  27. Dalton J, Narayanan R, Steiner M. Abstract P5-09-21: selective androgen receptor modulators (SARMs): enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer. Cancer Res. 2013;73(Suppl. 24):P5-09–21.

    Google Scholar 

  28. Tate C, Rhodes L, Segar HC, Driver J, Pounder FN, Burow M, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Conte P, Campone P, Pronzato D, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J Clin Oncol. 2009;27:15s(Suppl; abstr 1081).

    Article  Google Scholar 

  30. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.

    Article  CAS  PubMed  Google Scholar 

  31. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991–2001.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82.

    Article  CAS  PubMed  Google Scholar 

  33. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3 + Tregs and B7-H1 + /PD-1 + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008;8:57.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31(Suppl; abstr 3000).

  37. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717–27.

    Article  CAS  PubMed  Google Scholar 

  38. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.

    Article  CAS  PubMed  Google Scholar 

  39. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  40. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90.

    Article  CAS  PubMed  Google Scholar 

  41. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  PubMed  Google Scholar 

  42. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US). 2009 April 8. Identifier NCT00878709, Study Evaluating The Effects of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET) 2009. http://clinicaltrials.gov/show/NCT00878709.

  43. Park JW, Liu MC, Yee D, et al. Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 trial. 2014 AACR Annual Meeting. Abstract CT227. Presented April 7, 2014.

  44. Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Mol Cancer Ther. 2014;13:2991–3000.

    Article  CAS  PubMed  Google Scholar 

  45. Yardley DA WR, Melisko M, et al. A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Res. 2012;72(24s3):P6-10–01.

    Google Scholar 

  46. Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist. 2014;19(5):453–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Willyard C. ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med. 2013;19(6):655.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Cancer Center, Yale School of Medicine, 333 Cedar St, PO Box 208032, 06520-8032, New Haven, CT, USA

    Ami Jhaveri MD & Lajos Pusztai MD, DPhil

Authors
  1. Ami Jhaveri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lajos Pusztai MD, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ami Jhaveri MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jhaveri, A., Pusztai, L. New targets in breast cancer. memo 8, 86–91 (2015). https://doi.org/10.1007/s12254-015-0197-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0197-5

Keywords

Search

Navigation